Company Overview
Adagene Inc., a clinical stage biotechnology company, engages in the research, development, and production of monoclonal antibody drugs for cancers in the People's Republic of China. Its lead product candidate is the ADG126, a masked fully-human anti-CTLA-4 mAb which is in phase 1b/2 clinical development for the treatment of cancer. The company also develops ADG116, a fully human anti-CTLA-4 antibody generated using NEObody technology, which is in phase 1b/2 clinical trials to treat advanced/metastatic solid tumors; ADG206, which is in phase 1 clinical development to treat advanced metastatic solid tumors; ADG104, anti-PD-L1 monoclonal antibody which is in phase 2 clinical development; and ADG125, a novel anti-CSF-1R mAb which is in Phase 2 clinical development. In addition, it is developing ADG138, a HER2xCD3 POWERbody which is in pre clinical trial to treat low expressing tumors, as well as resistant/refractory tumors; ADG152, a CD20xCD3 POWERbody which is in preclincal trial to treat off-tumor toxicities; ADG153, a masked anti-CD47 IgG1 SAFEbody, wihx is in preclinical trial for the treatment of hematologic and solid tumor; and CD28 T-cell engagers, an anti-CD28 bispecific POWERbody TCEs to treat solid tumors. Adagene Inc. was incorporated in 2011 and is headquartered in Suzhou, China.
Why Investors Should Care
Net profit has compounded at 26.0% per year over the last five years.
Carries low leverage with a debt-to-equity ratio of 0.06.
Recent Developments
- Dec 2025 Revenue of $7.67M (+7332.8% YoY); net profit $-17.61M.
- 5-Year Trend Long-term compounding — revenue CAGR -6.2%, profit CAGR 26.0%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | -6.19% |
| 1 Year: | - |
Compounded Profit Growth
| 5 Years: | 25.99% |
| 1 Year: | - |
Stock Price Performance
| 1 Year: | +111.52% |
| 6 Months: | +14.43% |
| 3 Months: | +7.06% |
| 1 Month: | -15.09% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMAAbove
- RSI (14)39.70 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Profit CAGR of 26.0% over 5 years.
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
- Revenue declined at -6.2% CAGR over 5 years.
- Trading 27.0% below its 52-week high.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | ADAG Adagene Inc. PHARMA | 3.49 | -9.43 | $234.33M | 0.00% | -32.86% | -28.50% | -6.19% | 25.99% |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,123.91 | 37.80 | $1.00T | 0.60% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 269.12 | 31.22 | $648.55B | 1.98% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 248.78 | 70.48 | $439.62B | 2.78% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 148.46 | 118.77 | $366.28B | 2.31% | - | 6.96% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 400.84 | 25.74 | $359.79B | 2.47% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 137.70 | 20.80 | $261.73B | 3.36% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 160.04 | 23.99 | $248.20B | 2.00% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA | 603.02 | 32.49 | $222.97B | 0.29% | 8.14% | 13.51% | 8.81% | 12.95% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Revenue | - | 9.29M | 18.11M | 103.20K | 7.67M |
| Cost of Revenue | - | - | - | - | - |
| Gross Profit | - | - | - | - | - |
| Operating Expenses | - | 93.21M | 41.83M | 36.05M | 29.11M |
| Operating Income | - | -83.92M | -23.72M | -35.95M | -21.44M |
| EBITDA | - | -77.37M | -14.94M | -31.65M | -16.85M |
| Interest Expense | - | 693.32K | 1.11M | 851.87K | 463.13K |
| Pretax Income | - | -79.51M | -17.25M | -33.44M | -17.91M |
| Tax Provision | - | 459.06K | 1.69M | -17.55K | -297.86K |
| Net Income | - | -79.97M | -18.95M | -33.42M | -17.61M |
| Diluted EPS | - | -1.85 | -0.44 | -0.74 | -0.38 |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Total Assets | - | 152.40M | 115.73M | 89.27M | 78.26M |
| Current Assets | - | 149.32M | 113.44M | 87.78M | 77.38M |
| Cash & Equivalents | - | 143.76M | 109.93M | 85.19M | 74.52M |
| Inventory | - | - | - | - | - |
| Receivables | 3.00M | 0 | - | - | - |
| Total Liabilities | - | 69.31M | 45.17M | 38.74M | 42.91M |
| Current Liabilities | - | 55.08M | 31.46M | 38.18M | 25.17M |
| Long Term Debt | - | 14.15M | 13.54M | 417.34K | 1.14M |
| Total Debt | - | 27.97M | 22.31M | 18.49M | 6.26M |
| Total Equity | - | 83.09M | 70.56M | 50.52M | 35.35M |
| Shares Outstanding | - | 54.07M | 55.15M | 58.89M | 59.23M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Operating Cash Flow | - | -48.61M | -28.45M | -29.70M | -15.66M |
| Investing Cash Flow | - | -686.05K | -77.36K | 1.11M | 476.80K |
| Financing Cash Flow | - | 17.82M | -5.37M | 3.77M | 4.45M |
| Capital Expenditure | - | -690.94K | -85.01K | -33.58K | -17.05K |
| Free Cash Flow | - | -49.30M | -28.54M | -29.73M | -15.67M |
| Net Change in Cash | - | -31.47M | -33.90M | -24.82M | -10.74M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - |
| Operating Margin % | - | -903.1% | -131.0% | -34,835.4% | -279.5% |
| Net Margin % | - | -860.6% | -104.6% | -32,386.4% | -229.6% |
| ROE % | - | -96.2% | -26.9% | -66.2% | -49.8% |
| ROCE % | - | -86.2% | -28.1% | -70.4% | -40.4% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Jupiter Topco LLC | 9.93% | 6.67M | $22.07M |
| 2 | Siren, L.L.C. | 3.97% | 2.67M | $8.83M |
| 3 | Deerfield Management Company, L.P | 3.97% | 2.67M | $8.83M |
| 4 | Ameriprise Financial, Inc. | 2.56% | 1.72M | $5.68M |
| 5 | HSG Holding Ltd | 2.00% | 1.34M | $4.45M |
| 6 | Squadron Capital Management LLC | 1.86% | 1.25M | $4.14M |
| 7 | Dauntless Investment Group, LLC | 0.80% | 537.23K | $1.78M |
| 8 | Citadel Advisors Llc | 0.76% | 506.93K | $1.68M |
| 9 | Exome Asset Management LLC | 0.73% | 488.29K | $1.62M |
| 10 | Birchview Capital, LP | 0.36% | 240.00K | $794.40K |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for ADAG
Adagene to Participate in Three Upcoming Investor Conferences
SAN DIEGO and SUZHOU, China, Aug. 20, 2026 (GLOBE NEWSWIRE) -- Adagene Inc. (Nasdaq: ADAG) a platform-driven, clinical-stage biotechnology company transforming the discovery and development of novel antibody-based therapies, today announced…
Adagene (ADAG) Upgraded to Buy: Here's What You Should Know
Adagene (ADAG) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Adagene Spotlights ADG126 Strategy as Masked CTLA-4 Trial Advances in Colorectal Cancer
Adagene (NASDAQ:ADAG) Chief Strategy Officer Mickael Chane-Du outlined the company’s clinical strategy for its lead antibody program, ADG126, during a discussion with Stifel senior biotech analyst Stephen Willey, emphasizing the company’s f…
Adagene to Participate in Two Upcoming Investor Conferences
SAN DIEGO and SUZHOU, China, May 12, 2026 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene or the Company”) (Nasdaq: ADAG), a company transforming the discovery and development of novel antibody-based therapies, today announced that senior manage…
Adagene (ADAG) Partners With Incyte (INCY) to Evaluate Combination Therapy for Colorectal Cancer
Adagene Inc. (NASDAQ:ADAG) is one of the 10 Unstoppable Stocks That Could Double Your Money. Adagene Inc. (NASDAQ:ADAG) is one of the unstoppable stocks that could double your money. On April 2, Adagene announced a clinical collaboration wi…
Adagene Presents Two Posters at AACR 2026 with New Data Highlighting Muzastotug’s Potential as a Backbone Combination Therapy for Multiple Tumor Types
Triple combination of muzastotug + atezolizumab + bevacizumab resulted in much higher overall response rates (ORR) compared to the atezolizumab + bevacizumab control arm (66.7% vs. 32.5%, respectively by Investigator per HCC-specific Modifi…
ADAG — Frequently Asked Questions
What is the current share price of Adagene Inc. (ADAG)?
As of 2026-09-19 21:16 PDT, Adagene Inc. (ADAG) trades at $3.49 on NasdaqGM. Its 52-week range is $1.40 to $4.78.
What is the market capitalisation of ADAG?
Adagene Inc. (ADAG) has a market capitalisation of $234.33M on NasdaqGM.
What is the P/E ratio of ADAG?
ADAG trades at a trailing price-to-earnings (P/E) ratio of -9.43. The industry average P/E is 24.83. Its price-to-book (P/B) ratio is 2.48.
What is the return on equity (ROE) of ADAG?
ADAG has a return on equity (ROE) of -28.50%. Its return on capital employed (ROCE) is -32.86%.
Is ADAG a good stock to buy?
This page provides a data-driven analysis of Adagene Inc. (ADAG), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.